Cogent Biosciences, Inc. (COGT)
36.23
-0.50
(-1.36%)
USD |
NASDAQ |
Aug 24, 16:00
36.23
0.00 (0.00%)
After-Hours: 19:52
Cogent Biosciences Total Assets (Quarterly) : 834.55M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 834.55M |
| March 31, 2026 | 903.01M |
| December 31, 2025 | 937.61M |
| September 30, 2025 | 425.93M |
| June 30, 2025 | 274.82M |
| March 31, 2025 | 283.80M |
| December 31, 2024 | 327.90M |
| September 30, 2024 | 384.02M |
| June 30, 2024 | 429.94M |
| March 31, 2024 | 476.11M |
| December 31, 2023 | 313.44M |
| September 30, 2023 | 355.45M |
| June 30, 2023 | 392.37M |
| March 31, 2023 | 263.20M |
| December 31, 2022 | 300.81M |
| September 30, 2022 | 331.56M |
| June 30, 2022 | 366.05M |
| March 31, 2022 | 206.87M |
| Date | Value |
|---|---|
| December 31, 2021 | 232.09M |
| September 30, 2021 | 215.38M |
| June 30, 2021 | 228.52M |
| March 31, 2021 | 237.61M |
| December 31, 2020 | 250.92M |
| September 30, 2020 | 139.87M |
| June 30, 2020 | 31.06M |
| March 31, 2020 | 38.94M |
| December 31, 2019 | 49.42M |
| September 30, 2019 | 57.88M |
| June 30, 2019 | 69.31M |
| March 31, 2019 | 81.28M |
| December 31, 2018 | 85.93M |
| September 30, 2018 | 94.79M |
| June 30, 2018 | 102.72M |
| March 31, 2018 | 43.42M |
| December 31, 2017 | 49.12M |
| September 30, 2017 | 56.39M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 1.336B |
| ImmunityBio, Inc. | 628.50M |
| Erasca, Inc. | 435.05M |
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 302.16M |
| Shareholders Equity (Quarterly) | 532.39M |
| Debt to Equity Ratio | 0.4588 |
| Current Ratio | 13.57 |
| Net Debt Paydown Yield | -0.68% |